Poster Abstract Session:
50. C. difficile: Clinical and Outcomes
Thursday, October 18, 2012: 12:30 PM-2:00 PM
Room: SDCC Poster Hall F-H

Topical Category: N. Infection Epidemiology and Prevention and P. Pediatric and Perinatal Infections

Tracks: Epidemiology and Infection Control, Pediatric ID


Does Prolonging the Duration of C. difficile Infection Treatment Decrease Recurrences in Patients Receiving Concurrent Antibiotics?
Rafael Ponce-Terashima, MD ; Nuntra Suwantarat, MD ; Sirisha Kundrapu, M.D. ; Venkata Sunkesula, M.D, M.S ; Curtis J. Donskey, MD
  • Rafael's Poster-2.pdf (390.9 kB)

  • 294
    Predicting recurrence following a first episode of Clostridium difficile infection
    Jasmin Islam ; Vishal Navani ; Elizabeth Cheek ; Chakravarthi Rajkumar ; Jonathan Cohen ; Martin Llewelyn
  • J.ISLAM IDSA.pdf (582.5 kB)

  • 295
    Predicting the Risk of Clostridium difficile Infections Following an Outpatient Visit: Development and External Validation of a Pragmatic, Prognostic Risk Score
    Jennifer Kuntz, PhD ; Eric Johnson, PhD ; Marsha Raebel, PharmD ; Amanda Petrik ; Xiuhai Yang ; Micah Thorp, DO, MPH ; Steven Spindel, MD ; Nancy Neil, PhD ; David Smith, PhD

    Use of Vancomycin for the Management of Clostridium difficile Infection in U.S. Children's Hospitals
    Hayden Schwenk, MD ; Dionne A. Graham, PhD ; Tanvi Sharma, MD ; Thomas J. Sandora, MD, MPH
  • IDWeekPoster(vF2).pdf (900.4 kB)

  • 297
    Attributable Outcomes of Clostridium difficile Infection among Hospitalized Children
    Julia F. Shaklee, MD ; Rui Xiao, PhD ; A. Russell Localio, PhD ; Susan Coffin, MD, MPH ; Theoklis Zaoutis, MD, MSCE
  • IDWeek_Poster_2012.pdf (667.3 kB)

  • 298
    Examining clinical outcomes in a cohort of incident Clostridium difficile (CDI) patients using parametric survival models
    Eric Lofgren, MSPH ; Rebekah W. Moehring, MD ; David J. Weber, MD, MPH, FIDSA, FSHEA ; Deverick J. Anderson, MD, MPH

    Clinical Impact of Probiotics Among Patients Receiving Antibiotics with High Risk of Acquiring Clostridium difficile Infections
    Justine Dickson, PharmD ; Tai-Tsang Chen, PhD ; Whitney (Yu-Hui) Hung, Pharm D, BCPS
  • Slide1.png (291.7 kB)

  • 301
    Characterizing the Cytokine Response to Clostridium difficile Infection
    Krishna Rao, MD ; Seth Walk, MS, PhD ; Dejan Micic, MD ; Nicole Falkowski ; Jill Mogle, LPN ; Cathrin Ring, MS ; John Erb-Downward, PhD ; Vincent B Young, MD, PhD ; Gary Huffnagle, PhD ; David Aronoff, MD, FIDSA

    Development and Optimization of High Throughput Assays to Measure Neutralizing Antibodies against Clostridium difficile Toxins
    Jinfu Xie ; Julie Zorman ; Lani Indrawati ; Melanie Horton ; Keri Soring ; Joseph Antonello ; Yuhua Zhang ; Su Wang ; Susan Secore ; Lorraine Hernandez ; Matthew Miezeiewski ; Julie Skinner ; Jean-Luc Bodmer ; Jon Heinrichs, PhD
  • IDWeek poster Sep2012 final.pdf (206.1 kB)

  • 303
    Treatment of Refractory Clostridium difficile With Nitazoxanide
    Samuel Aitken, Pharm.D. ; Michael Ruggero, Pharm.D. ; Nilesh Amin, Pharm.D. ; Jeffrey Topal, MD

    Evaluation of a Clostridium difficile Infection Treatment Guideline with Clinical Pharmacy and Medical Microbiology Involvement at a Major Canadian Teaching Hospital
    Shirley S.T. Yeung, BSc(Pharm) ; Janice Yeung, PharmD ; Tim T.Y. Lau, PharmD ; Theodore Steiner, MD ; Leslie Forrester, BA(Hons), MA, MSc ; Mandeep Saran, PharmD ; Elizabeth Bryce, MD FRCPC
  • CDI_Poster_SYEUNG.pdf (240.5 kB)

  • 306
    Management of Clostridium difficile infection (CDI). Results from a Pan-European Survey: Perceptions and Reality
    Mark Wilcox, MD ; Ed J. Kuijper, MD, PhD ; Annie Jones, MSc ; David Bradshaw, BSc (Hons) ; Christian Felter, MD

    Antimicrobial choice in Clostridium difficile infection: Taking recurrence risk into account
    Christian Felter, MD ; Christopher Longshaw, PhD ; Annie Jones, MSc ; David Bradshaw, BSc (Hons)

    A systematic review of risk factors for recurrences of Clostridium difficile infection
    Claire Nour Abou Chakra, MSc ; Jacques Pépin, M.D. ; Stephanie Sirard, M.Sc. ; Louis Valiquette, MD

    Outcomes of Clostridium difficile infection in Veterans with Spinal Cord Injury/Disorder (SCI/D)
    Charlesnika Evans, MPH, PhD ; Stuart Johnson, MD, FIDSA ; Stephen Burns, MD ; Linda Poggensee, MS ; Bridget Smith, PhD ; Barry Goldstein, MD, PhD ; Stephen Kralovic, MD, MPH ; Dale Gerding, MD, FIDSA
  • Evans cdiff 10-2012.pdf (244.6 kB)

  • 310
    Validation of a Clostridium difficile recurrence score
    David Eyre, BM, BCh ; Tim Peto, MB BS, DPhil ; David Wyllie, PhD ; Kate Dingle, PhD ; David Griffiths, BSc ; John Finney ; Lily O'Connor, BSc ; Alison Vaughan, BSc ; Derrick Crook, MB, BCh ; Mark Wilcox, MD ; A. Sarah Walker, PhD

    Management of Clostridium difficile infections: First results of the pan-European PROHIBIT Survey
    Sonja Hansen, MD ; Walter Zingg, MD ; Frank Schwab, MSc ; Michael Behnke, MSc ; Hugo Sax, MD ; Didier Pittet, MD, MS ; Petra Gastmeier, MD ; Prohibit Consortium

    The Impact of Cefepime as First Line Therapy for Neutropenic Fever on Clostridium difficile rates among Hematologic and Oncologic Patients
    Eavan Muldoon, MB, BCh, MD ; Lauren Epstein, MD ; Tanya Logvinenko ; Susan Murray ; Shira Doron, MD ; David Snydman, MD, FIDSA
  • cefepimeIDSA 9th oct.pdf (273.7 kB)

  • 316
    Development and Validation of a Recurrent Clostridium difficile (CDI) Risk Prediction Model
    Marya Zilberberg, MD, MPH ; Kimberly Reske, MPH ; Margaret Olsen, PhD, MPH ; Yan Yan, MD, PhD ; Sheila Thomas, PharmD ; Erik Dubberke, MD, MSPh

    Recurrence of C. difficile infection (CDI): A risk-stratified analysis of Fidaxomicin vs Vancomycin
    Basem Alraddadi, MBBS ; Lauren Epstein, MD ; David Snydman, MD, FIDSA ; Yoav Golan, MD MS
  • IDSA2012 alraddadi Final.pdf (662.6 kB)

  • 318
    Impact of the 2010 SHEA-IDSA Practice Guidelines in Understanding Risk for Clostridium difficile Infection
    Jason Leung, BS ; Robert Burke, RN, MA ; Dale Ford, RN, MPH ; Gale Garvin, RN, MEd ; Cathy Korn, RN, MPH ; Carol Sulis, MD ; Nahid Bhadelia, MD, MA

    CME Credits:

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 17th with the exception of research findings presented at the IDWeek press conferences.